March 27, 2019 — The Centers for Medicare and Medicaid Services (CMS) proposed to update its national coverage policy ...

Johns Hopkins Medicine now has access to the first Ultra-High Resolution computed tomography (UHR CT) system for research capabilities, delivering twice the resolution of today’s CT systems, thanks to the installation of the Aquilion Precision from Canon Medical Systems USA Inc. The system will be used to expand research capabilities in studies of liver disease and bone loss, as well as investigations in lung disease and coronary artery disease.

March 26, 2019 — A toilet seat-based cardiovascular monitoring system created by a team of Rochester Institute of ...

Patients who stopped taking aspirin one month after receiving a stent in the heart’s arteries but continued taking the P2Y12 inhibitor clopidogrel fared significantly better after one year compared with those who followed the standard practice of continuing both medications, according to recent research. Stopping aspirin early was found to be superior in terms of the trial’s primary endpoint, a composite of death from cardiovascular causes, heart attack, clotting near the stent, stroke and major bleeding. The data were presented at the American College of Cardiology’s (ACC) 68th Annual Scientific Session, March 16-18 in New Orleans.

Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American College of Cardiology (ACC) Scientific Sessions & Expo, March 16-18 in New Orleans. Bempedoic acid is being developed as a complementary, cost-effective, convenient, once-daily, oral therapy for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). Bempedoic acid and the bempedoic acid/ezetimibe combination tablet new drug applications have been submitted to the U.S. Food and Drug Administration (FDA), and are under regulatory review for marketing authorization by the European Medicines Agency.